Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelics Business

News
Novamind Secures Coverage from 4 Insurers for IV Ketamine Treatment
11/11/2021
Tom Valentino, Digital Managing Editor
Novamind announced it has obtained approval for direct billing of IV ketamine for treatment-resistant depression from Blue Cross Blue Shield, University of Utah, PEHP Health & Benefits, and MBA Benefit Administrators.
Novamind announced it has obtained approval for direct billing of IV ketamine for treatment-resistant depression from Blue Cross Blue Shield, University of Utah, PEHP Health & Benefits, and MBA Benefit Administrators.
Novamind announced it has...
11/11/2021
Behavioral Healthcare Executive
News
Cybin Launches Psychedelic Facilitator Training Program
11/04/2021
Tom Valentino, Senior Editor
Cybin, a biotechnology firm specializing in progressing psychedelic therapeutics, has announced the launch of the EMBARK psychedelic facilitator training program.
Cybin, a biotechnology firm specializing in progressing psychedelic therapeutics, has announced the launch of the EMBARK psychedelic facilitator training program.
Cybin, a biotechnology firm...
11/04/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Mind Cure, Awakn, MindMed, Revitalist
10/28/2021
Tom Valentino, Senior Editor
Mind Cure has signed a letter of intent to distribute Awakn Life Sciences’ ketamine-assisted therapy for alcohol use disorder in the US and Canada. MindMed has announced plans to expand its drug development pipeline. Revitalist, meanwhile, is...
Mind Cure has signed a letter of intent to distribute Awakn Life Sciences’ ketamine-assisted therapy for alcohol use disorder in the US and Canada. MindMed has announced plans to expand its drug development pipeline. Revitalist, meanwhile, is...
Mind Cure has signed a letter of...
10/28/2021
Behavioral Healthcare Executive
Scott Theaman, Beyond Marketing
Perspectives
6 Marketing Best Practices for Ketamine Clinics
10/26/2021
Scott Theaman
A ketamine clinic can provide an ideal alternative for individuals struggling with treatment-resistant depression. Here are a series of tips for developing a growth strategy to connect with more potential patients.
A ketamine clinic can provide an ideal alternative for individuals struggling with treatment-resistant depression. Here are a series of tips for developing a growth strategy to connect with more potential patients.
A ketamine clinic can provide an...
10/26/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Numinus Wellness, Awakn Life Sciences
10/21/2021
Tom Valentino, Senior Editor
Numinus Wellness has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived psilocybin extract, while an Awakn Life Sciences facility in the UK has received a key approval to begin offering...
Numinus Wellness has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived psilocybin extract, while an Awakn Life Sciences facility in the UK has received a key approval to begin offering...
Numinus Wellness has finalized...
10/21/2021
Behavioral Healthcare Executive
News
Novamind Launches Palliative Program, Obtains DEA Licenses
10/13/2021
Tom Valentino, Senior Editor
Novamind has launched a psychedelic palliative care program at its Murray, Utah, facility, and also obtained DEA licenses for conducting psilocybin research.
Novamind has launched a psychedelic palliative care program at its Murray, Utah, facility, and also obtained DEA licenses for conducting psilocybin research.
Novamind has launched a...
10/13/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: NeonMind to Launch Clinics, Delix Secures $70 Million to Develop Psychdelics Analogs
10/01/2021
Tom Valentino, Senior Editor
NeonMind announced it plans to establish a network of clinics that will provide psychedelic-based psychiatry treatments starting in 2022, while Delix Therapeutics has closed a $70 million Series A financing round to fund development of...
NeonMind announced it plans to establish a network of clinics that will provide psychedelic-based psychiatry treatments starting in 2022, while Delix Therapeutics has closed a $70 million Series A financing round to fund development of...
NeonMind announced it plans to...
10/01/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Ketamine One Signs LOI to Provide Therapy for Vets with PTSD
09/23/2021
Tom Valentino, Senior Editor
Ketamine One has signed a letter of interest with Veterans Services USA to provide therapy at Blue Island Therapy Center in Illinois. Meanwhile, Awakn Life Sciences has acquired a facility in Norway.
Ketamine One has signed a letter of interest with Veterans Services USA to provide therapy at Blue Island Therapy Center in Illinois. Meanwhile, Awakn Life Sciences has acquired a facility in Norway.
Ketamine One has signed a letter...
09/23/2021
Behavioral Healthcare Executive
News
Delic Builds Psychedelics Portfolio with Deal for Ketamine Wellness Centers
09/20/2021
Tom Valentino, Senior Editor
Psychedelics wellness company Delic on Monday announced a deal to acquire Ketamine Wellness Centers, creating one of the largest psychedelic organizations in the United States.
Psychedelics wellness company Delic on Monday announced a deal to acquire Ketamine Wellness Centers, creating one of the largest psychedelic organizations in the United States.
Psychedelics wellness company...
09/20/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Wesana Commits $1.5 Million to Support MAPS Research on MDMA-Assisted Therapy for TBI
09/15/2021
Tom Valentino, Senior Editor
Wesana Health Holdings is committing an initial $1.5 million to assessing the viability of the Multidisciplinary Association for Psychedelics Studies’ (MAPS) MDMA-assisted therapy for the treatment of traumatic brain injuries. Lennham...
Wesana Health Holdings is committing an initial $1.5 million to assessing the viability of the Multidisciplinary Association for Psychedelics Studies’ (MAPS) MDMA-assisted therapy for the treatment of traumatic brain injuries. Lennham...
Wesana Health Holdings is...
09/15/2021
Behavioral Healthcare Executive

Advertisement

Stay in the Know

Behavioral Healthcare Executive Newsletter

Popular Articles

Ron Manderscheid, PhD
Perspectives
Social Isolation Epidemic Must Be Confronted Head-On
05/18/2023
Ron Manderscheid, PhD
With a rise in loneliness putting the nation at an increased risk of depression, anxiety, and substance use, US Surgeon General Vivek Murthy, MD, has proposed a national strategy for improving social connection.
With a rise in loneliness putting the nation at an increased risk of depression, anxiety, and substance use, US Surgeon General Vivek Murthy, MD, has proposed a national strategy for improving social connection.
With a rise in loneliness...
05/18/2023
Behavioral Healthcare Executive
Rosalynn Carter: Stigma has `a long way to go`
01/23/2013
Former First Lady reflects 40-plus years of fighting stigma, advocating for those with mental illnesses, in this exclusive interview.
Former First Lady reflects 40-plus years of fighting stigma, advocating for those with mental illnesses, in this exclusive interview.
Former First Lady reflects...
01/23/2013
Behavioral Healthcare Executive
News
Rogers to be Honored for Leadership in Combating Opioid Epidemic
10/22/2019
U.S. Rep. Hal Rogers, the Kentucky Congressman who has led various federal initiatives to combat the opioid epidemic, will be honored on Wednesday in Washington, D.C., by Mothers Against Prescription Drug Abuse (MAPDA) with the organization’s...
U.S. Rep. Hal Rogers, the Kentucky Congressman who has led various federal initiatives to combat the opioid epidemic, will be honored on Wednesday in Washington, D.C., by Mothers Against Prescription Drug Abuse (MAPDA) with the organization’s...
U.S. Rep. Hal Rogers, the...
10/22/2019
Behavioral Healthcare Executive
News
AMA Releases Full Language of New CPT Code for Psychedelic Therapies
07/06/2023
Tom Valentino, Digital Managing Editor
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural...
07/06/2023
Behavioral Healthcare Executive
News
Americans support coverage of all levels of care for mental and addictive disorders, survey says
12/18/2012
A national study conducted by Public Opinion Strategies for the National Association of Psychiatric Health Systems (NAPHS) says that 93% of Americans agree that these types of services should be covered.
A national study conducted by Public Opinion Strategies for the National Association of Psychiatric Health Systems (NAPHS) says that 93% of Americans agree that these types of services should be covered.
A national study conducted by...
12/18/2012
Behavioral Healthcare Executive

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement